Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Reduce” by Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned a consensus rating of “Reduce” from the seven analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company.

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th.

Bayer Aktiengesellschaft Stock Up 1.6 %

OTCMKTS:BAYRY opened at $5.13 on Monday. Bayer Aktiengesellschaft has a fifty-two week low of $4.94 and a fifty-two week high of $9.79. The firm has a 50-day simple moving average of $6.78 and a two-hundred day simple moving average of $7.21. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 2.02%. The business had revenue of $10.96 billion during the quarter. On average, analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.